Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
IOVA Stock Chart & Stats
$2.55
-$0.33(-4.53%)
At close: 4:00 PM EST
$2.55
-$0.33(-4.53%)
Day’s Range― - ―
52-Week Range$1.64 - $6.16
Previous CloseN/A
Volume2.95M
Average Volume (3M)10.92M
Market Cap
$1.01B
Enterprise Value$740.16M
Total Cash (Recent Filing)$300.80M
Total Debt (Recent Filing)$52.49M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 03, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding396,967,960
10 Day Avg. Volume11,662,377
30 Day Avg. Volume10,921,753
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)3.02
Price to Sales (P/S)13.07
P/FCF Ratio-5.89
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.96
Enterprise Value/Gross Profit7.63
Enterprise Value/Ebitda-2.01
Forecast
1Y Price Target
$9.50Price Target Upside272.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ValidationPositive nonsquamous NSCLC data validate the tumor-infiltrating lymphocyte strategy and support lifileucel's potential adoption in an area with limited treatment options.
Operational Efficiency And LiquidityImproved gross margins from operational efficiencies and cost saves, combined with a cash balance that supports operations into mid-2027, lower funding risk and bolster execution credibility.
Regulatory ApprovalsApproval in Canada and anticipated approvals in the UK and Australia in 1H26 create new commercial markets that can expand patient access and revenue potential.
Bears Say
Amtagvi Sales RevisionsAnalyst downgrades to Amtagvi sales expectations reduce near-term revenue visibility and pressure valuation assumptions.
Earnings And CredibilityRecent earnings misses and subsequent estimate cuts erode investor confidence and make credibility rebuilding a central challenge for management.
Investor Sentiment And TechnicalsPersistent investor skepticism and weak share-price technicals, including trading below key moving averages, limit upside even if operational progress continues.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $1.64 and its highest was $6.16 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $1.01B.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Mar 03, 2026 which is in 29 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.258 by $0.008.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.17.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 396,967,960 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.258. Following the earnings report the stock price went up 27.624%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (272.55% Upside)
$9.50 (272.55% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 71%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.93%
12-Months-Change
Fundamentals
Return on Equity
-53.89%
Trailing 12-Months
Asset Growth
-8.69%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting significant revenue growth, successful strategic restructuring, and promising clinical data in lung cancer. However, challenges remain in expense management, global market expansion, and community ATC adoption.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$9.50
▲(272.55% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
0.30% Insiders
11.01% Mutual Funds
0.02% Other Institutional Investors
73.70% Public Companies and Individual Investors